We therefore applied this IMR-based immunoassay to evaluate the potential diagnostic accuracy of a panel of four biomarkers—α-synuclein, total and phosphorylated tau (p-Tau181), and Aβ42 in the plasma of patients with PD and APS. This evidence concerns the gene MAPT and autoimmune polyendocrinopathy.